

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

DATE 2000 10/23/2002	FIRST NAMED INVENTOR SYLVAIN ORENGA	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/23/2002	SYLVAIN ORENGA		
T 🔿			
OLIFF & BERRIDGE, PLC P.O. BOX 19928		EXAMI	VER
ALEXANDRIA, VA 22320		NAVARRO, ALBERT MARK	
		ART UNIT	PAPER NUMBER
		1645 DATE MAILED: 10/23/2002	11
			ART UNIT

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. **09/486,037** 

Mark Navarro

Applicant(s)

----

Examiner

Art Unit 1645

Orenga



The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
Period for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In mailing date of this communication.	
<ul> <li>If the period for reply specified above is less than thirty (30) days, a reply within the     If NO period for reply is specified above, the maximum statutory period will apply a     Failure to reply within the set or extended period for reply will, by statute, cause the     Any reply received by the Office later than three months after the mailing date of the     earned patent term adjustment. See 37 CFR 1.704(b).</li> </ul>	nd will expire SIX (6) MONTHS from the mailing date of this communication. e application to become ABANDONED (35 U.S.C. § 133).
Status	
1) Responsive to communication(s) filed on	· ·
2a) ☐ This action is <b>FINAL</b> . 2b) ☒ This act	ion is non-final.
3) Since this application is in condition for allowance a closed in accordance with the practice under Ex pair	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposition of Claims	
4) 💢 Claim(s) <u>1-28</u>	is/are pending in the application.
4a) Of the above, claim(s)	is/are withdrawn from consideration.
5)  Claim(s)	is/are allowed.
6) 💢 Claim(s) <u>1-4, 6-8, and 13-19</u>	is/are rejected.
7) 💢 Claim(s) <u>5, 9-12, and 20-28</u>	is/are objected to.
8) Claims	are subject to restriction and/or election requirement.
Application Papers	
9) $\square$ The specification is objected to by the Examiner.	
10) The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.
Applicant may not request that any objection to the d	rawing(s) be held in abeyance. See 37 CFR 1.85(a).
11) The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.
If approved, corrected drawings are required in reply t	to this Office action.
12) The oath or declaration is objected to by the Exami	ner.
Priority under 35 U.S.C. §§ 119 and 120	
13) 💢 Acknowledgement is made of a claim for foreign process.	iority under 35 U.S.C. § 119(a)-(d) or (f).
a) $\square$ All b) $\square$ Some* c) $\square$ None of:	
1.   Certified copies of the priority documents have	e been received.
2. $\square$ Certified copies of the priority documents hav	e been received in Application No
application from the International Bure	
*See the attached detailed Office action for a list of the	
14) ☐ Acknowledgement is made of a claim for domestic	
a) L The translation of the foreign language provisiona	
15) Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. 33 12U and/or 121.
Attachment(s)  1) X Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:

Application/Control Number: 09/486,037 Page 2

Art Unit: 1645

## **DETAILED ACTION**

Applicant's amendment filed August 9, 2002 (Paper Number 13) has been received and entered. Claims 1-28 are pending in the instant application.

All grounds of rejection in the office action mailed February 11, 2002 are withdrawn.

The following new grounds of rejection are applied to the claims:

## Claim Rejections - 35 USC § 112

1. Claims 2-3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Regarding claims 2-3, the phrase "optionally" renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(d).

V

Application/Control Number: 09/486,037 Page 3

Art Unit: 1645

2. Claim 16 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claim is vague and indefinite in the recitation of "in that the activator consists of... and/or... and or..." One of skill in the art would be unable to determine the metes and bounds of the claimed invention. For instance the transitional phrase "consists" is deemed to be closed and include only what is recited. However Applicant's language leaves one of skill in the art to guess the identity of what is included in the medium based upon the multiple "and/or" recitations. Without a clear idea of what is encompassed by the term consisting of one of skill in the art would be unable to determine the metes and bounds of the claimed invention.

3. Claim 17 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claim is vague and indefinite in the recitation of a "derivative." One of skill in the art would be unable to determine the metes and bounds of a derivative. Since it is unclear how the protein is altered to form a derivative referred to in the claims, there is no way for the person of skill in the art to ascribe a discrete and identifiable class of compounds which are derivatives.

Page 4

Application/Control Number: 09/486,037

Art Unit: 1645

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

4. Claims 1-4 and 6-8 are rejected under 35 U.S.C. 102(b) as being anticipated by Kaneko et al.

The claims are drawn to culture medium for the specific identification and/or differentiation of *Candida albicans* and *Candida tropicalis* yeast, comprising a chromogenic or fluorigenic substrate, which can be hydrolyzed by an enzyme of the hexosaminidase family,

Page 5

Application/Control Number: 09/486,037

Art Unit: 1645

wherein the medium also comprises at least one compound that selectively inhibits the hexosaminidase activity of *C. tropicalis*.

Kaneko et al (U.S. Patent Number 5,272,072) disclose of a composition comprising 5bromo-4-chloro-3-indolyl-β-D-glucuronic acid and dimethyl formamide. (See column 9).

In view that 5-bromo-4-chloro-3-indolyl-β-D-glucuronic is a chromogenic substrate that can be hydrolyzed by an enzyme of the hexosaminidase family and that dimethyl formamide selectively inhibits the hexosaminidase activity of C. tropicalis, the disclosure of Kaneko et al is deemed to anticipate the claimed invention.

It is noted that Kaneko et al do not disclose culturing Candida with the composition, however culturing Candida with the composition is merely an intended use of the composition and therefore carries no patentable weight.

5. Claims 13-19 are rejected under 35 U.S.C. 102(e) as being anticipated by Wong-Madden et al.

The claims are drawn to medium for the specific identification and/or differentiation of Candida albicans and Candida tropicalis yeasts, wherein said medium comprises two substrates, a first chromogenic or fluorigenic substrate that can be hydrolyzed by an enzyme from the hexosaminidase family, and a second chromogenic or fluorigenic substrate that can be hydrolyzed by an enzyme from the glucosidase family.

Application/Control Number: 09/486,037

Page 6

Art Unit: 1645

Wong-Madden (U.S. Publication 2002/0137176) disclose of multiple chromogenically labeled substrates in a composition. (See pages 6-9).

In view that Wong-Madden disclose of multiple chromogenically labeled substrates that can be hydrolyzed by an enzyme from the hexosaminidase family, and chromogenically labeled substrates that can be hydrolyzed by an enzyme from the glucosidase family, the disclosure of Wong-Madden et al is deemed to anticipate the claimed invention.

Claims 5, 9-12, and 20-28 are objected to as depending upon a rejected base claim, however claims 5, 9-12 and 20-28 are free of the prior art of record.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mark Navarro, whose telephone number is (703) 306-3225. The examiner

Art Unit: 1645

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Group 1645 by facsimile transmission. Papers should by faxed to Group 1645 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the official Gazette 1096 OG 30 (November 15, 1989). The CMI Fax Center number is (703) 308-4242.

Mark Navarro

Primary Examiner

October 16, 2002